326 related articles for article (PubMed ID: 10313123)
1. Orphan Drug Act on congressional agenda.
von Oehsen WH
Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123
[TBL] [Abstract][Full Text] [Related]
2. Orphan drug development in the United States.
Groft SC
CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306
[TBL] [Abstract][Full Text] [Related]
3. [Orphan drugs: some legal, ethical and economics aspects].
Pabst JY
Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
[TBL] [Abstract][Full Text] [Related]
4. Developing treatments for inborn errors: incentives available to the clinician.
Haffner ME
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
[TBL] [Abstract][Full Text] [Related]
5. Clinical studies of safety and effectiveness of orphan products; availability of grants; request for applications. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Notice.
Fed Regist; 1999 Jul; 64(141):40012-6. PubMed ID: 10558579
[TBL] [Abstract][Full Text] [Related]
6. The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing.
Breslow LH
Harvard J Legis; 2003; 40(1):133-93. PubMed ID: 16594116
[TBL] [Abstract][Full Text] [Related]
7. Orphan drugs: the question of products liability.
Scharf SF
Am J Law Med; 1985; 10(4):491-513. PubMed ID: 3911776
[TBL] [Abstract][Full Text] [Related]
8. The Orphan Drug Act and the Federal Government's Orphan Products Development Program.
Finkel MJ
Public Health Rep; 1984; 99(3):313-6. PubMed ID: 6429731
[TBL] [Abstract][Full Text] [Related]
9. Orphan products development and some methods for maximizing the usefulness of research on rare diseases.
Finkel MJ
Prog Clin Biol Res; 1985; 197():11-8. PubMed ID: 4070285
[No Abstract] [Full Text] [Related]
10. [Orphan drugs].
Galeffi C
Ann Ist Super Sanita; 1991; 27(2):341-3. PubMed ID: 1661568
[TBL] [Abstract][Full Text] [Related]
11. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
Wellman-Labadie O; Zhou Y
Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
[TBL] [Abstract][Full Text] [Related]
12. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
13. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform.
Clissold DB
Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989
[No Abstract] [Full Text] [Related]
14. Orphan Drug Act.
Van Woert MH
Prog Clin Biol Res; 1985; 197():7-9. PubMed ID: 4070300
[No Abstract] [Full Text] [Related]
15. Clinical studies of safety and effectiveness of orphan products; availability of grants; request for applications--FDA. Notice.
Fed Regist; 1998 Aug; 63(150):41855-9. PubMed ID: 10181724
[TBL] [Abstract][Full Text] [Related]
16. The Orphan Drug Act: an engine of innovation? At what cost?
Rohde DD
Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720
[No Abstract] [Full Text] [Related]
17. View from the Nation's Capital.
Freishtat HW
J Clin Psychopharmacol; 1985 Apr; 5(2):117-9. PubMed ID: 3988970
[No Abstract] [Full Text] [Related]
18. Orphan drug development for the treatment of rare chronic diseases.
Moore ES
Tex Hosp; 1988 Jul; 44(2):20-1. PubMed ID: 10288218
[No Abstract] [Full Text] [Related]
19. Developing drugs for developing countries.
Ridley DB; Grabowski HG; Moe JL
Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
[TBL] [Abstract][Full Text] [Related]
20. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.
Arno PS; Bonuck K; Davis M
Milbank Q; 1995; 73(2):231-52. PubMed ID: 7776947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
